Immunogenicity & researc Summit 2014 (Immunogenicity Assessment & Clinical Relevance )

The impact of Immunogenicity on efficacy is costing the industry vast amounts every year and denying patients much needed treatment. Moreover the danger of adverse reactions is ever present. Assessment of immunogenicity continues to be hampered by complications such as target interference, interfering drug and pre-existing antibody, while setting of cut points and interpretation of data is complicated. Cambridge Healthtech Institute's Sixth Annual Immunogenicity Assessment & Clinical Relevance conference will enable investigators to work out a risk assessment immunogenicity strategy for their product that satisfies themselves and the regulatory authorities that their product is safe and efficacious.